PDCD1 and neoplasm: Because the efficacy of PD-1/PD-L1 inhibitors is influenced by the MMR function of the tumor, PD-1/PD-L1 inhibitors are not expected to be effective for pMMR tumors even in patients with Lynch syndrome.